Overview
TPST market data
Price History
TPST price chart · 1M
- O
- 1.09
- H
- 1.09
- L
- 1.08
- C
- 1.08
- Vol
- 1,503.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.09
- Previous Close
- $1.10
- Day High
- $1.09
- Day Low
- $1.08
- 52 Week High
- $2.44
- 52 Week Low
- $0.87
- 7 Day Return
- +0.00%
- 30 Day Return
- +12.44%
- 90 Day Return
- -38.29%
- 1 Year Return
- -53.65%
- Daily Notional Volume
- $1.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.33 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.72 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -9,760.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.84 – $12.23 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $18.9M · P/B 2.12 · P/S 62.85.
Company News
Tempest Therapeutics Says Justin Trojanowski To Resign As Principal Financial Officer Effective Sept 1; Nicholas Rossettos Appointed As CFO, Principal Financial OfficerBenzinga · Aug 24, 2026, 8:46 PM
8-K filing — Tempest Therapeutics, Inc. (TPST)SEC EDGAR · Aug 24, 2026, 8:43 PM
Tempest Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 8,910,579 Shares Of Common StockBenzinga · Aug 21, 2026, 8:49 PM
Tempest Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.Benzinga · Aug 14, 2026, 6:43 PM
Tempest Therapeutics Secures $50M Equity Purchase Agreement With Lincoln Park CapitalBenzinga · Aug 13, 2026, 9:22 PM
Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) EstimateBenzinga · Aug 13, 2026, 8:42 PM
Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026Benzinga · Jul 21, 2026, 11:10 AM
Tempest Unveils Next-Gen In Vivo CAR-T Platform; To Advance TPST-4003 Into Q4 2026 Trial In MG, MS PatientsBenzinga · Jul 15, 2026, 11:04 AM
Tempest Therapeutics Files Prospectus For Offering 2.427M Common Shares On Behalf Of Selling ShareholdersBenzinga · Jun 26, 2026, 8:10 PM
Tempest Therapeutics Nicholas Maestas Resigns As CFO Effective June 5, 2026; Appoints Justin Trojanowski As Principal Financial Officer Effective June 5, 2026Benzinga · Jun 4, 2026, 9:10 PM